VEGFA and hepatocellular carcinoma: The combination therapy of atezolizumab, an immune checkpoint inhibitor, and bevacizumab, an anti-vascular endothelial growth factor antibody (Atezo + Bev), demonstrated efficacy in the IMbrave150 trial and has been established as the standard first-line treatment for unresectable HCC [4].